CABALETTA BIO, INC. Diluted Shares Outstanding (Weighted Average)
CABALETTA BIO, INC. (CABA) reported Diluted Shares Outstanding (Weighted Average) of 151.16 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-13
- CABALETTA BIO, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 151.16M shares, a 144.29% increase year-over-year.
- CABALETTA BIO, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 112.03M shares, a 120.77% increase year-over-year.
- CABALETTA BIO, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-06-30 was 61.88M shares.
- CABALETTA BIO, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-03-31 was 50.74M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month |
|---|---|---|
| 2026-06-30 | 151.16M shares 10-Q · filed 2026-08-13 | 131.70M shares 10-Q · filed 2026-08-13 |
| 2026-03-31 | 112.03M shares 10-Q · filed 2026-05-14 | |
| 2025-06-30 | 61.88M shares 10-Q · filed 2026-08-13 | 56.34M shares 10-Q · filed 2026-08-13 |
| 2025-03-31 | 50.74M shares 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |